The value in triple negative mutation adenocarcinoma (10.5 ± 22.6, n = 71) was higher by 1.3-fold than that in EGFR-, KRAS-, or ALK-positive adenocarcinoma (8.0 ± 17.9, n = 219), but no significant difference was found (p = 0.31) (Figure 3B). The gene discussed is KRAS; the disease is adenocarcinoma.